Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) was $13.16 for the day, down -2.66% from the previous closing price of $13.52. In other words, the price has decreased by -$2.66 from its previous closing price. On the day, 1.27 million shares were traded. DNA stock price reached its highest trading level at $14.0991 during the session, while it also had its lowest trading level at $13.155.
Ratios:
Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 08 ’25 when Che Austin bought 2,200 shares for $15.21 per share.
Coen Steven P. sold 5,609 shares of DNA for $84,135 on Oct 01 ’25. The insider now owns 5,503 shares after completing the transaction at $15.00 per share. On Sep 09 ’25, another insider, HENRY CHRISTIAN O, who serves as the Director of the company, sold 10,000 shares for $11.06 each. As a result, the insider received 110,600 and left with 24,310 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 800380672 and an Enterprise Value of 684533376. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.38 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 2.966 whereas that against EBITDA is -2.966.
Stock Price History:
The Beta on a monthly basis for DNA is 1.54, which has changed by 0.68934536 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $17.58, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 4.84%, while the 200-Day Moving Average is calculated to be 28.99%.
Shares Statistics:
DNA traded an average of 1.72M shares per day over the past three months and 2124840 shares per day over the past ten days. A total of 43.82M shares are outstanding, with a floating share count of 40.53M. Insiders hold about 27.88% of the company’s shares, while institutions hold 61.91% stake in the company. Shares short for DNA as of 1759190400 were 5844738 with a Short Ratio of 3.40, compared to 1756425600 on 6710084. Therefore, it implies a Short% of Shares Outstanding of 5844738 and a Short% of Float of 12.740000000000002.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Ginkgo Bioworks Holdings Inc (DNA).The consensus estimate for the next quarter is -$1.27, with high estimates of -$1.17 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$5.16 and -$5.33 for the fiscal current year, implying an average EPS of -$5.25. EPS for the following year is -$4.34, with 3.0 analysts recommending between -$3.51 and -$4.85.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $40M to a low estimate of $37.5M. As of. The current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $89.05MFor the next quarter, 4 analysts are estimating revenue of $40.19M. There is a high estimate of $43.7M for the next quarter, whereas the lowest estimate is $37.08M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $181M, while the lowest revenue estimate was $175M, resulting in an average revenue estimate of $177.07M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $202.55M in the next fiscal year. The high estimate is $210M and the low estimate is $194.9M.
